Schedule 13G ownership disclosure
Kura Oncology Inc
Common Stock, par value $0.0001 per share · CUSIP: 50127T109
Event date: 2025-01-27
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BIOTECHNOLOGY VALUE FUND L P
Shares: 3,041,280.00 · Class: 3.9%
- BVF I GP LLC
Shares: 3,041,280.00 · Class: 3.9%
- BIOTECHNOLOGY VALUE FUND II LP
Shares: 2,451,183.00 · Class: 3.1%
- BVF II GP LLC
Shares: 2,451,183.00 · Class: 3.1%
- Biotechnology Value Trading Fund OS LP
Shares: 306,446.00 · Class: 0.4%
- BVF Partners OS Ltd.
Shares: 306,446.00 · Class: 0.4%
- BVF GP HOLDINGS LLC
Shares: 5,492,463.00 · Class: 7.0%
- BVF PARTNERS L P/IL
Shares: 5,912,554.00 · Class: 7.5%
- BVF INC/IL
Shares: 5,912,554.00 · Class: 7.5%
- LAMPERT MARK N
Shares: 5,912,554.00 · Class: 7.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-25-000249
- Form type
- SCHEDULE 13G
- Filer
- BIOTECHNOLOGY VALUE FUND L P
- CIK
- CIK 918923
- Filed
- Feb 04, 2025
- Reporting period
- Jan 27, 2025
- Description
- Schedule 13G beneficial ownership